Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

Abstract

OBJECTIVES:

To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a tumour necrosis factor alpha inhibitor.

METHODS:

Patients were randomised equally to placebo, CP-690,550 5, 15 or 30 mg twice daily for 6 weeks, with 6 weeks' follow-up. The patient's assessment of arthritis pain (pain), patient's assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) and Short Form-36 (SF-36) were recorded.

RESULTS:

At week 6, significantly more patients in the CP-690,550 5, 15 and 30 mg twice-daily groups experienced a 50% improvement in pain compared with placebo (44%, 66%, 78% and 14%, respectively), clinically meaningful reductions in HAQ-DI (> or =0.3 units) (57%, 75%, 76% and 36%, respectively) and clinically meaningful improvements in SF-36 domains and physical and mental components.

CONCLUSIONS:

CP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.

• Authors: J H Coombs, B J Bloom, F C Breedveld, M P Fletcher, D Gruben, J M Kremer, R Burgos-Vargas, B Wilkinson, C A F Zerbini, S H Zwillich
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 69 Issue 2 Pg. 413-6 (Feb 2010) ISSN: 1468-2060 [Electronic] England
• PMID: 19587388 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antirheumatic Agents
• Piperidines
• Protein Kinase Inhibitors
• Pyrimidines
• Pyrroles
• tofacitinib
• JAK3 protein, human
• Janus Kinase 3

Topics

• Antirheumatic Agents (administration & dosage, therapeutic use)
• Arthritis, Rheumatoid (complications, drug therapy, physiopathology)
• Dose-Response Relationship, Drug
• Epidemiologic Methods
• Female
• Humans
• Janus Kinase 3 (antagonists & inhibitors)
• Male
• Middle Aged
• Pain (drug therapy, etiology)
• Pain Measurement
• Piperidines
• Protein Kinase Inhibitors (administration & dosage, therapeutic use)
• Pyrimidines (administration & dosage, therapeutic use)
• Pyrroles (administration & dosage, therapeutic use)
• Recovery of Function
• Treatment Outcome